MRSN

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Mersana Therapeutics Inc

NASDAQ | MRSN

27.43

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 13, 2025)

$44.27M

Market Cap

-

P/E Ratio

-14.79

EPS

$70.72

52 Week High

$5.21

52 Week Low

HEALTHCARE

Sector

MRSN Chart

Recent Chart
Price Action

MRSN Technicals

Tags:

MRSN Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $39M
Total Revenue $40M
Cost Of Revenue $1.6M
Costof Goods And Services Sold $1.6M
Operating Income -$73M
Selling General And Administrative $41M
Research And Development $73M
Operating Expenses $114M
Investment Income Net -
Net Interest Income $4.6M
Interest Income $8.4M
Interest Expense $3.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$69M
Income Tax Expense $418K
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$65M
Ebitda -$63M
Net Income -$69M

Revenue & Profitability

Earnings Performance

MRSN Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $145M
Total Current Assets $137M
Cash And Cash Equivalents At Carrying Value $108M
Cash And Short Term Investments $108M
Inventory -
Current Net Receivables -
Total Non Current Assets $7.8M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $27M
Other Current Assets $2.3M
Other Non Current Assets -
Total Liabilities $154M
Total Current Liabilities $62M
Current Accounts Payable $4.3M
Deferred Revenue -
Current Debt -
Short Term Debt $16M
Total Non Current Liabilities $92M
Capital Lease Obligations $5.1M
Long Term Debt $11M
Current Long Term Debt $13M
Long Term Debt Noncurrent -
Short Long Term Debt Total $29M
Other Current Liabilities $20M
Other Non Current Liabilities $8K
Total Shareholder Equity -$9.5M
Treasury Stock -
Retained Earnings -$896M
Common Stock $12K
Common Stock Shares Outstanding $4.9M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$82M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.6M
Capital Expenditures $132K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $11M
Cashflow From Financing $4.1M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $486K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$69M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $39M
Total Revenue $40M
Cost Of Revenue $1.6M
Costof Goods And Services Sold $1.6M
Operating Income -$73M
Selling General And Administrative $41M
Research And Development $73M
Operating Expenses $114M
Investment Income Net -
Net Interest Income $4.6M
Interest Income $8.4M
Interest Expense $3.9M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.6M
Income Before Tax -$69M
Income Tax Expense $418K
Interest And Debt Expense -
Net Income From Continuing Operations -$69M
Comprehensive Income Net Of Tax -
Ebit -$65M
Ebitda -$63M
Net Income -$69M

MRSN News

MRSN Profile

Mersana Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to pioneering innovative Antibody Drug Conjugates (ADCs) to meet significant unmet needs in oncology. The company is advancing a strong pipeline of proprietary ADCs designed to enhance targeted therapy efficacy and improve patient outcomes. With a commitment to transforming cancer treatment, Mersana continues to progress through pivotal clinical trials and collaborates with key industry players, positioning itself as a vital contributor to the future landscape of cancer therapeutics.

NVVE
+204.60%
$0.47
LPTX
+368.57%
$2.05
TNMG
+37.18%
$0.41
CMND
+11.56%
$0.34
VINE
-16.56%
$0.44
ONDS
+19.05%
$6.56
RUBI
+16.35%
$0.23
NVDA
-3.58%
$186.86
VHAI
0.00%
$0.00
SOND
+8.82%
$0.18
PFE
-0.25%
$25.80
SOFI
-11.85%
$28.39
PLUG
-8.79%
$2.49
ASST
-10.46%
$1.15
BITF
-17.98%
$2.60
TSLA
-6.48%
$402.66
WTO
-30.89%
$0.02
ACHR
-8.15%
$7.94
DRCT
+44.06%
$0.28
BYND
-9.41%
$1.01
YDKG
-14.75%
$0.02
DNN
-3.86%
$2.49
F
-1.22%
$13.28
SGBX
+32.21%
$3.16
ETHD
+14.44%
$5.15
AXDX
-61.36%
$0.03
MGRX
-32.38%
$1.19
INTC
-5.85%
$35.67
RGTI
-10.95%
$25.20
AMD
-4.22%
$247.96
NIO
-3.33%
$6.23
CSCO
+4.62%
$77.38
CIFR
-14.09%
$14.93
PLTR
-6.81%
$171.61
SNAP
-5.66%
$8.57
RIVN
-6.25%
$16.42
TLRY
-8.13%
$1.13
MARA
-11.31%
$12.78
GRAB
-4.31%
$5.54
CRCL
-4.76%
$82.19
CAN
-10.18%
$0.97
ADAP
-15.14%
$0.05
NOK
+1.73%
$7.02
CHR
+3.90%
$0.04
QBTS
-11.45%
$23.37
IREN
-12.65%
$48.65
AAPL
-0.19%
$272.95
ASBP
-7.65%
$0.10
BBD
-0.13%
$3.67
WULF
-7.59%
$11.68
SOUN
-7.70%
$12.22
BTBT
-11.26%
$2.52
DIS
-7.77%
$107.58
AMZN
-2.71%
$237.58
APLT
-70.33%
$0.27
RMBL
+60.50%
$3.21
UGRO
-18.97%
$0.24
LNW
-3.71%
$86.22
AAL
-2.89%
$13.07
ADD
-25.47%
$0.05
BAC
-2.24%
$52.89
IONZ
+20.63%
$5.67
SMCI
-7.43%
$35.09
BTE
+4.12%
$3.15
T
+0.44%
$25.76
CRWV
-9.03%
$77.71
RIG
-3.14%
$4.00
NBIS
-7.68%
$94.36
SRM
+53.27%
$10.30
CLSK
-10.12%
$11.98
GPUS
-10.41%
$0.30
EPWK
-38.09%
$0.04
QS
-7.41%
$13.55
HPE
-2.80%
$22.82
BMNR
-9.37%
$36.76
IONQ
-10.67%
$45.29
MU
-3.24%
$236.95
CMG
+5.06%
$31.32
KVUE
+0.68%
$16.78
WBD
-0.22%
$22.14
PLTD
+6.47%
$6.91
HOOD
-9.51%
$120.33
HIMS
-7.77%
$35.98
GOOGL
-2.83%
$278.57
BURU
-8.32%
$0.25
BTG
-1.79%
$4.10
AMCR
+1.96%
$8.57
TWOH
-5.66%
$0.00
WLGS
-5.57%
$0.04
RIOT
-10.21%
$13.88
QUBT
-9.96%
$10.03
BE
-18.28%
$103.55
APLD
-7.56%
$26.41
PLTZ
+13.00%
$7.04
JD
-1.71%
$30.71
VSA
-20.34%
$0.23
DKNG
-5.77%
$29.69
MSFT
+0.48%
$511.14
JOBY
-9.32%
$14.78
NGD
-4.15%
$7.26
NVVE
+204.60%
$0.47
LPTX
+368.57%
$2.05
TNMG
+37.18%
$0.41
CMND
+11.56%
$0.34
VINE
-16.56%
$0.44
ONDS
+19.05%
$6.56
RUBI
+16.35%
$0.23
NVDA
-3.58%
$186.86
VHAI
0.00%
$0.00
SOND
+8.82%
$0.18
PFE
-0.25%
$25.80
SOFI
-11.85%
$28.39
PLUG
-8.79%
$2.49
ASST
-10.46%
$1.15
BITF
-17.98%
$2.60
TSLA
-6.48%
$402.66
WTO
-30.89%
$0.02
ACHR
-8.15%
$7.94
DRCT
+44.06%
$0.28
BYND
-9.41%
$1.01
YDKG
-14.75%
$0.02
DNN
-3.86%
$2.49
F
-1.22%
$13.28
SGBX
+32.21%
$3.16
ETHD
+14.44%
$5.15
AXDX
-61.36%
$0.03
MGRX
-32.38%
$1.19
INTC
-5.85%
$35.67
RGTI
-10.95%
$25.20
AMD
-4.22%
$247.96
NIO
-3.33%
$6.23
CSCO
+4.62%
$77.38
CIFR
-14.09%
$14.93
PLTR
-6.81%
$171.61
SNAP
-5.66%
$8.57
RIVN
-6.25%
$16.42
TLRY
-8.13%
$1.13
MARA
-11.31%
$12.78
GRAB
-4.31%
$5.54
CRCL
-4.76%
$82.19
CAN
-10.18%
$0.97
ADAP
-15.14%
$0.05
NOK
+1.73%
$7.02
CHR
+3.90%
$0.04
QBTS
-11.45%
$23.37
IREN
-12.65%
$48.65
AAPL
-0.19%
$272.95
ASBP
-7.65%
$0.10
BBD
-0.13%
$3.67
WULF
-7.59%
$11.68
SOUN
-7.70%
$12.22
BTBT
-11.26%
$2.52
DIS
-7.77%
$107.58
AMZN
-2.71%
$237.58
APLT
-70.33%
$0.27
RMBL
+60.50%
$3.21
UGRO
-18.97%
$0.24
LNW
-3.71%
$86.22
AAL
-2.89%
$13.07
ADD
-25.47%
$0.05
BAC
-2.24%
$52.89
IONZ
+20.63%
$5.67
SMCI
-7.43%
$35.09
BTE
+4.12%
$3.15
T
+0.44%
$25.76
CRWV
-9.03%
$77.71
RIG
-3.14%
$4.00
NBIS
-7.68%
$94.36
SRM
+53.27%
$10.30
CLSK
-10.12%
$11.98
GPUS
-10.41%
$0.30
EPWK
-38.09%
$0.04
QS
-7.41%
$13.55
HPE
-2.80%
$22.82
BMNR
-9.37%
$36.76
IONQ
-10.67%
$45.29
MU
-3.24%
$236.95
CMG
+5.06%
$31.32
KVUE
+0.68%
$16.78
WBD
-0.22%
$22.14
PLTD
+6.47%
$6.91
HOOD
-9.51%
$120.33
HIMS
-7.77%
$35.98
GOOGL
-2.83%
$278.57
BURU
-8.32%
$0.25
BTG
-1.79%
$4.10
AMCR
+1.96%
$8.57
TWOH
-5.66%
$0.00
WLGS
-5.57%
$0.04
RIOT
-10.21%
$13.88
QUBT
-9.96%
$10.03
BE
-18.28%
$103.55
APLD
-7.56%
$26.41
PLTZ
+13.00%
$7.04
JD
-1.71%
$30.71
VSA
-20.34%
$0.23
DKNG
-5.77%
$29.69
MSFT
+0.48%
$511.14
JOBY
-9.32%
$14.78
NGD
-4.15%
$7.26
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.